Additional analyses from the givinostat clinical development program review observations on weight-based flexible dosing, characterization of thrombocytopenia, correlations between pharmacodynamic ...
SEATTLE, Nov. 17, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback